Efavirenz

Generic Name: Efavirenz

Brand Names: Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₉ClF_₃NO_₂

CAS Number: 154598-52-4

Unique Ingredient Identifier: JE6H2O27P8

Background: Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.

For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen.

Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.

Indication: For use in combination treatment of HIV infection (AIDS)

Associated Conditions: Human Immunodeficiency Virus Type 1 (HIV-1) Infection

Clinical Trials

Bristol-Myers Squibb: 150 Years of Pharmaceutical Innovation and Global Healthcare Leadership

12 years ago

• Bristol-Myers Squibb, founded in 1858, has evolved from a small Brooklyn pharmaceutical company to a global healthcare leader with approximately 28,000 employees and focus on six core therapeutic areas. • The company's landmark merger in 1989 created a pharmaceutical powerhouse with combined profits of $1.3 billion, leading to over 60 product lines generating $50+ million in annual sales by 1995. • BMS maintains a robust pipeline with 40 compounds in exploratory development and 6 in late-stage development, despite facing patent expiration challenges for key drugs like Plavix and Avapro.

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy